Gilead advances in CymaBay acquisition with antitrust clearance By Investing.com

Published on 11 Mar 2024 on Investing.com

Gilead advances in CymaBay acquisition with antitrust clearance

Read the rest of the article

Start tracking your investments with Statfolio

The first-quarter 2024 reporting cycle of the Medical sector is about to pick up pace this week. ...

Zacks via Yahoo Finance 24 Apr 2024

Gilead Sciences Inc. GILD is set to report first-quarter 2024 results on Apr 25, after market clo...

Zacks via Yahoo Finance 22 Apr 2024

Following an investigation announced in November last year, the FDA said on Thursday that it woul...

Benzinga 19 Apr 2024

The U.S. Food and Drug Administration said on Thursday cancer therapies that use CAR-T technology...

Reuters 18 Apr 2024

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it mig...

Zacks via Yahoo Finance 16 Apr 2024

Broadening our ability to tackle breast cancer are several biotech developments including from...

KAMR Amarillo 11 Apr 2024

The most oversold stocks in the health care sector presents an opportunity to buy into undervalue...

Benzinga 11 Apr 2024

Bristol Myers Squibb BMY announced that the FDA approved a label expansion for chimeric antigen r...

Zacks via Yahoo Finance 8 Apr 2024

Investing.com 8 Apr 2024

In a recent move, Gilead Sciences, Inc. (NASDAQ: GILD ) has increased its stake in Xilio...

Investing.com 3 Apr 2024